Tuesday, October 03, 2023 8:18:55 PM
Oct. 3, 2023 4:39 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX
Biotech Rat
Value, Special Situations, Momentum, Long/Short Equity
Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.
The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.
Analysts predict a conservative $4 a share or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well.
One such example is the strategic Partnership with Tyligand Biosciences for Onapristone extended release (ONA-XR) intended for use in hormone-driven breast, ovarian, and endometrial cancer. The partnership seems to be going according to pan. For immediate refresher see the following link. Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
Here is a link to the Onapristine ER trial (Oath) in the Journal of Clinical Oncology. Oath trial
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Analyst's Disclosure: I/we have a beneficial long position in the shares of CNTX either through stock ownership, options, or other derivatives.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Looking at the Context Therapeutics 5 year chart allows for a quick snapshot of the beginning turnaround in the share price .
Recent CNTX News
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 • GlobeNewswire Inc. • 05/02/2024 11:31:53 AM
- Context Therapeutics Announces $100 Million Private Placement • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers • GlobeNewswire Inc. • 04/01/2024 11:30:00 AM
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/21/2024 11:43:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:30:51 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 09:24:50 PM
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 11/09/2023 09:15:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:04:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 01:04:29 PM
- Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 • GlobeNewswire Inc. • 10/31/2023 01:00:00 PM
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting • GlobeNewswire Inc. • 09/27/2023 01:00:00 PM
- Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 08/09/2023 08:10:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:04:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 12:11:05 PM
- Context Therapeutics to Participate in Two August 2023 Investor Conferences • GlobeNewswire Inc. • 08/01/2023 11:30:00 AM
- Context Therapeutics Reports First Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 05/10/2023 08:39:59 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM